Chengdu PriMed Huaying Bio-tech Co., Ltd, jointly invested and established by Sichuan PriMed Bio-tech Group Co., Ltd. and Chengdu International Biological Industry Town Investment & Development Co., Ltd. successfully signed collaboration agreements with Medical Research Council Technology (MRCT), Brown University and Fourth Medical University on October, 10th, 2016.

Successful signing of the agreements has fully integrated unique and advanced non-human primate models with state-of-the-art technology of drug evaluation and development, focusing on the screening and drug development of major disease areas including cardiovascular disease, liver disease, kidney disease and central nervous system diseases, which will enhance the core competence of Chinese pharmaceuticals and establish a leading global platform for innovative drug development of major diseases.